Editas Medicine, Inc.
EDIT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650664
In the last 90 days, Editas Medicine, Inc. insiders filed 0 open-market purchases and 3 sales; 218 institutions reported holding it in 13F filings for Q2 2026, worth $386.4M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $422.3M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $19.1K in total
- 3
- 13F holdersQ2 2026, +10 vs. previous quarter
- 218
- 13F valueReported value at the end of Q2 2026
- $386.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $40.5M
- +25.4% year over year
- Net income, FY2025
- -$160.1M
- No comparable prior period
- Free cash flow, FY2025
- -$165.8M
- No comparable prior period
- Revenue, Q3 FY2026
- $10.4M
- +37.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $160.1M (395.0% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 38.2M
- Shares sold short
- Change
- +1.08M
- +2.9% vs. previous
- Days to cover
- 14.34
- At average daily volume
Superinvestors holding EDIT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding EDIT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Editas Medicine, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)4:27 PM ET | Sep 3 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −709 | $3.04 | −$2.15K | −1.1%61.7K after | 10b5-1 |
| Sep 4, 2026 (view filing)4:25 PM ET | Sep 3 | 1 day | Parison AmySVP, Chief Financial Officer | SSale | −453 | $3.04 | −$1.38K | −3.2%13.8K after | 10b5-1 |
| Sep 4, 2026 (view filing)4:22 PM ET | Sep 3 | 1 day | O'Neill Gilmore NeilCEO | SSale | −5.12K | $3.04 | −$15.6K | −2.1%243.2K after | 10b5-1 |
| Aug 5, 2026 (view filing)4:07 PM ET | Aug 3 | 2 days | Parison AmySVP, Chief Financial Officer | SSale | −678 | $2.58 | −$1.75K | −4.5%14.3K after | 10b5-1 |
| Jul 29, 2026 (view filing)4:51 PM ET | Jul 28 | 1 day | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −4.93K | $2.67 | −$13.2K | −7.3%62.4K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Parison AmySVP, Chief Financial Officer | SSale | −464 | $2.70 | −$1.25K | −3.0%15.0K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | O'Neill Gilmore NeilCEO | SSale | −15.4K | $2.70 | −$41.5K | −5.8%248.3K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SSale | −731 | $2.70 | −$1.97K | −1.1%67.3K after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | O'Neill Gilmore NeilCEO | SSale | −5.39K | $2.02 | −$10.9K | −2.0%263.7K after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Parison AmySVP, Chief Financial Officer | SSale | −474 | $2.02 | −$957.48 | −3.0%15.4K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 218 holdersThe largest institutional positions in Editas Medicine, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 11,111,111 | $36.0M | 0.87% | +11,111,111 | New |
| BlackRock, Inc. | 10,589,990 | $34.3M | 0.00% | +1,326,678+14.3% | Added |
| Ra Capital Management, L.P. | 8,889,000 | $28.8M | 0.25% | +8,889,000 | New |
| Commodore Capital LP | 8,889,000 | $28.8M | 1.72% | +8,889,000 | New |
| ADAR1 Capital Management, LLC | 8,889,000 | $28.8M | 1.35% | +8,889,000 | New |
| Vanguard Capital Management LLC | 6,141,336 | $19.9M | 0.00% | +1,936,967+46.1% | Added |
| Paradigm Biocapital Advisors LP | 5,586,625 | $18.1M | 0.34% | +5,586,625 | New |
| Opaleye Management Inc. | 3,861,930 | $12.5M | 1.13% | +1,934,933+100.4% | Added |
| Vanguard Portfolio Management LLC | 3,598,339 | $11.7M | 0.00% | +449,769+14.3% | Added |
| Woodline Partners LP | 3,555,497 | $11.5M | 0.04% | +3,555,497 | New |
Holders of 5% or more of EDIT
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Editas Medicine, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Commodore Capital LP | 13G | 9.90%16.0M shares | New | Jun 2, 20261 filing | Jun 2, 2026 | SEC |
| TCG Crossover GP III, LLC | 13G | 9.90%15.8M shares | New | Jun 3, 20261 filing | Jun 3, 2026 | SEC |
| BlackRock, Inc. | 13G | 7.80%11.9M shares | +2.83 ppfrom 4.97% | Apr 17, 20253 filings | Oct 27, 2026 | SEC |
| ADAR1 Capital Management, LLC | 13G | 5.80%8.89M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Ra Capital Management, L.P. | 13G | 5.80%8.89M shares | New | Jun 3, 20261 filing | Jun 3, 2026 | SEC |
Politician trades
All politician trades in EDIT4 members of Congress reported 12 trades in Editas Medicine, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| May 19, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
| May 1, 2021 |  Donald S. Beyer, Jr. House · VA | Sell | $1K-$15K |
| Apr 1, 2021 | Donald S. Beyer, Jr. House · VA | Sell | $1K-$15K |
| Feb 19, 2021 |  Bill Hagerty Senate · TN | Sell (partial) | $15K-$50K |
| Dec 1, 2020 | Donald S. Beyer, Jr. House · VA | Buy | $1K-$15K |
House · NY · May 19, 2023
Sell$1K-$15K
House · VA · May 1, 2021
Sell$1K-$15K
House · VA · Apr 1, 2021
Sell$1K-$15K
Senate · TN · Feb 19, 2021
Sell (partial)$15K-$50K
House · VA · Dec 1, 2020
Buy$1K-$15K